Keytruda (pembrolizumab)

Size: px
Start display at page:

Download "Keytruda (pembrolizumab)"

Transcription

1 Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. FDA-Approved Indications Classic Hodgkin Lymphoma Keytruda is indicated for the treatment of adult and pediatric patients with refractory classical Hodgkin Lymphoma (chl), or who have relapsed after 3 or more prior lines of therapy. Melanoma Keytruda is indicated for the treatment of patients with unresectable or metastatic melanoma Non-small Cell Lung Cancer Keytruda, as a single agent, is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) 50%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations Keytruda, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS 1%) as determined by an FDA-approved test with disease progression on or after platinum-based chemotherapy. Keytruda is indicated for Ppatients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving pembrolizumab. Keytruda, in combination with pemetrexed and carboplatin, is indicated for the first-line treatment of patients with metastatic nonsquamous NSCLC. Head and Neck Cancer Keytruda is indicated for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy Urothelial Carcinoma Keytruda is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy

2 Keytruda 2 Keytruda is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy Microsatellite Instability-High Cancer Keytruda is indicated for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient o Solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, or o Colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan Compendial Uses Unresectable or metastatic melanoma as a single agent for: o First-line therapy o Second-line or subsequent therapy (if not already given) following disease progression in patients with performance status (PS) 0-2 if anti PD-1 monotherapy not previously used o After maximum clinical benefit from BRAF targeted therapy for patients with PS 0-2 o Re-induction therapy for patients with PS 0-2 who experience disease control and have no residual toxicity but subsequently experience disease (treatment for disease progression/relapse >3 months after treatment discontinuation. and previous response) Merkel cell carcinoma (non-melanoma skin cancer) o Treatment for distant metastatic disease or disseminated recurrence (with or without surgery or radiation therapy [RT]) Non-small cell lung cancer o Single agent therapy for recurrence or metastasis if PD-L1 expression-positive ( 50%) as First-line therapy for tumors that are EGFR, ALK, and ROS1 negative or unknown Subsequent therapy for sensitizing EGFR mutation-positive tumors and prior erlotinib, afatinib, gefitinib, or osimertinib therapy Subsequent therapy for ALK rearrangement-positive tumors and prior crizotinib, ceritinib, or alectinib therapy Subsequent therapy for ROS1 rearrangement-positive tumors and prior crizotinib therapy o Treatment for recurrence or metastasis for tumors of nonsquamous cell histology in combination with carboplatin and pemetrexed (if pembrolizumab not previously given) for patients with performance status 0-1 as first-line therapy for EGFR, ALK, ROS1, BRAF, and PD-L1 negative or unknown first-line or subsequent therapy for BRAF V600E-mutation positive tumors subsequent therapy for sensitizing EGFR mutation-positive tumors and prior erlotinib, afatinib, gefitinib, or osimertinib therapy subsequent therapy for ALK rearrangement-positive tumors and prior crizotinib, ceritinib, alectinib, or brigatinib therapy subsequent therapy for ROS1 rearrangement-positive tumors and prior crizotinib therapy subsequent therapy for PD-L1 expression-positive ( 50%) tumors and EGFR, ALK, ROS1, and BRAF negative or unknown

3 Keytruda 3 o Single agent as subsequent therapy (if not already given) for metastatic disease in patients with performance status 0-2 and tumors with PD-L1 expression levels 1% Following progression on a first-line cytotoxic regimen For further progression on other systemic therapy Head and neck cancer o Therapy as a single agent if disease progression on or after platinum-containing chemotherapy for: newly diagnosed T4b, any N, M0 disease; unresectable nodal disease with no metastases; or for patients who are unfit for surgery and performance status (PS)3 metastatic (M1) disease at initial presentation or recurrent/persistent disease with distant metastases, or unresectable locoregional recurrence or second primary with prior radiation therapy (RT) and PS 0-2 unresectable locoregional recurrence without prior RT and PS 3e Bladder Cancer o Used as a single agent for Bladder Cancer clinical stage T4b or T2-4a, N1-3 disease, or for recurrence post cystectomy, or for metastatic disease first line therapy in cisplatin ineligible patients subsequent systemic therapy o Used as a single agent for primary treatment for pprimary ccarcinoma of the uurethra clinical stages T3-4 cn1-2 disease or cn1-2 palpable inguinal lymph nodes as first line therapy in cisplatin ineligible patients o Used as single agent for metastatic disease of the uupper GIU ttract ttumors as first line therapy in cisplatin ineligible patients subsequent systemic therapy o Used as single agent for metastatic disease for Urothelial Carcinoma of the Prostate as first line therapy in cisplatin ineligible patients subsequent systemic therapy Patients with PS 3 with newly diagnosed T4b, any N, M0 disease; unresectable nodal disease with no metastases; unresectable locoregional recurrence and no prior RT, or for patients who are unfit for surgery Unresectable locoregional recurrence or second primary in patients with PS 0-2 who have received prior RT Metastatic disease Bone Cancer Ewing Sarcoma, Mesenchymal Chondrosarcoma, Osteaosarcoma, Dedifferentiated Chondrosarcoma, and High Grade Undifferentiated Pleomorphic Sarcoma single-agent therapy for patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dmmr) tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options Classical Hodgkin lymphoma o Refractory or relapsed disease, as a single agent for refractory disease if Deauville 4-5 or for relapsed disease in patients previously treated with brentuximab vedotin o Palliative therapy, as a single agent for relapsed or refractory disease in older adults (age >60) CNS Cancers o Limited (1-3) Brain Metastases

4 Keytruda 4 consider for treatment for recurrent disease as a single agent for brain metastases if active against primary tumor (melanoma and non-small cell lung cancer) o Multiple (>3) Brain Metastases treatment for recurrent stable systemic disease as a single agent for brain metastases if active against primary tumor (melanoma and non-small cell lung cancer) Colorectaln Cancer o Primary treatment as a single agent for unresectable metachronous metastases (defective mismatch repair/high microsatellite instability[dmmr/msi-h] and previous adjuvant FOLFOX (fluorouracil, leucovorin and oxaliplatin) or CapeOX (capecitabine and oxaliplatin) within the past 12 months o Initial therapy as a single agent for patients with unresectable advanced or metastatic disease (defective mismatch repair/high microsatellite instability ([dmmr/msi-h] only) who are not appropriate for intensive therapy o Subsequent therapy as a single agent (if nivolumab or pembrolizumab not previously given) for unresectable advanced or metastatic disease (defective mismatch repair/high microsatellite instability [dmmr/msi-h] only) following previous oxaliplatin- irinotecanand/or fluoropyrimidine-based therapy Classical Hodgkin lymphoma o Refractory or relapsed disease, as a single agent o Palliative therapy, as a single agent Malignant Pleural Mesothelioma o Subsequent systemic therapy as a single agent Merkel cell carcinoma (non-melanoma skin cancer) Treatment for distant metastatic disease or disseminated recurrence (with or without surgery or radiation therapy [RT]) Rectal Cancer Primary treatment as a single agent for unresectable metachronous metastases (defective mismatch repair/high microsatellite instability [dmmr/msi-h] only) and previous adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or CapeOX (capecitabine and oxaliplatin) within the past 12 months Initial therapy as a single agent for patients with unresectable advanced or metastatic disease (defective mismatch repair/high microsatellite instability [dmmr/msi-h] only) who are not appropriate for intensive therapy Subsequent therapy as a single agent (if nivolumab or pembrolizumab not previously given) for unresectable advanced or metastatic disease (defective mismatch repair/high microsatellite instability [dmmr/msi-h] only) following previous oxaliplatin- irinotecanand/or fluoropyrimidine-based therapy B. REQUIRED DOCUMENTATION The following information is necessary to initiate the prior authorization review: For initial therapy

5 Keytruda 5 o Current oncology notes, clinical notes (including previous treatment history), and any pertinent pathology reports and/or imaging studies supporting the diagnosis of unresectable or metastatic melanoma For NSCLC, a copy of the laboratory report with PD-L1 test results must be submitted o For continuation therapy o Documentation demonstrating lack of disease progression on therapy (e.g, clinical notes, laboratory tests, and any pertinent pathology reports and/or imaging studies) C. PRESCRIBER RESTRICTIONS Keytruda must be recommended by an oncologist or a hematologist. D. CRITERIA FOR APPROVAL 1. Melanoma a. Initial authorization of 3 months may be granted for members who are prescribed Keytruda for initial/first-line therapy or for re-induction therapy when the following criteria are met: i. Member has unresectable or metastatic disease ii. Keytruda will be used as a single agent b. Initial authorization of 3 months may be granted for members who are prescribed Keytruda for second-line or subsequent therapy when the following criteria are met: i. Member has unresectable or metastatic disease ii. Keytruda will be used as a single agent iii. Member experienced disease progression following previous therapy or maximum clinical benefit from BRAF targeted therapy. Examples of previous therapy: Nivolumab (Opdivo) Nivolumab (Opdivo)/ipilimumab (Yervoy) Vemurafenib (Zelboraf) Dabrafenib (Tafinlar)/trametinib (Mekinist) 2. Non-small cell lung cancer a. Initial authorization of 3 months may be granted for members who are prescribed Keytruda for first-line therapy or subsequent therapy following targeted therapy only when the following criteria are met: i. Member has metastatic disease, AND ii. Member has non-squamous NSCLC and Keytruda will be used in combination with pemetrexed and carboplatin, OR iii. Tumor has high PD-L1 expression (Tumor Proportion Score [TPS] 50%; a copy of laboratory test result is required), AND iv. Patients with tumors known to have EGFR, ALK or ROS1 genomic aberrations are required to have had progression on an FDA-approved therapy for one of these aberrations, AND v. Keytruda will be used as a single agent b. Initial authorization of 3 months may be granted for members who are prescribed Keytruda for subsequent therapy following chemotherapy or other systemic therapy when the following criteria are met: i. Member has metastatic disease ii. Tumor is positive for PD-L1 expression (TPS 1%; a copy of laboratory test result is required)

6 Keytruda 6 iii. Keytruda will be used as a single agent iv. Member has experienced disease progression on or after first-line cytotoxic therapy, or further progression of other systemic therapy (documentation with previous therapy must be submitted) 3. Head and neck cancer for head and neck cancer when the following criteria are met: a. Member has recurrent or metastatic disease, or b. Member has any of the following conditions: diagnosed with T4b disease, unresectable nodal disease, or unfit for surgery, and c. Histology is squamous cell carcinoma, and d. Member has experienced disease progression on or after platinum-containing chemotherapy 4. Classical Hodgkin lymphoma for relapsed or refractory Classical Hodgkin lymphoma when the following criteria are met: Member has relapsed or refractory disease, or Keytruda will be used as palliative therapy 5. Urothelial carcinoma for urothelial carcinoma when the following criteria are met: a. Member has locally advanced or metastatic disease, and b. Member meets any of the following (i., ii. Or iii): i. Not eligible to receive cisplatin-containing chemotherapy ii. Experienced disease progression during or following platinum-containing chemotherapy iii. Experienced disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy 6. Microsatellite instability-high / Mismatch repair deficient cancer for microsatellite instability-high or mismatch repair deficient cancer when the following criteria are met: a. Solid tumor/colorectal cancer has high microsatellite instability or defective mismatch repair b. Cancer is unresectable or metastatic c. Keytruda is not prescribed for a pediatric patient with a central nervous system cancer d. For colorectal cancer: Experienced disease progression following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan regimenno further criteria. e. For other solid tumors: i. Experienced disease progression following previous treatment, and ii. There are no other satisfactory alternative treatment options available 7. Merkel cell carcinoma

7 Keytruda 7 for Merkel cell carcinoma and have distant metastatic disease or disseminated recurrence. E. CONTINUATION OF THERAPY 1. No previous authorization/precertification: All members (including new members and members currently receiving treatment without prior authorization) must meet criteria for initial approval in section D. 2. Reauthorization: Members who were previously approved for Keytruda by HMSA/CVS may request reauthorizations after their initial approval. Approval for an additional 3 months may be granted if the following information is supplied: A current oncology note documenting the patient s response to treatment showing no progression of disease Current imaging studies and other objective measures showing no progression of disease when compared with previous results Authorization of 3 months may be granted to members requesting authorization for continuation of therapy if Keytruda was previously authorized by HMSA/CVS and documentation supporting lack of disease progression on Keytruda therapy is provided. F. DOSAGE AND ADMINISTRATION Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. G. ADMINISTRATIVE GUIDELINES Precertification is required. Please refer to the HMSA medical policy web site for the fax form. H. IMPORTANT REMINDER The purpose of this Medical Policy is to provide a guide to coverage. This Medical Policy is not intended to dictate to providers how to practice medicine. Nothing in this Medical Policy is intended to discourage or prohibit providing other medical advice or treatment deemed appropriate by the treating physician. Benefit determinations are subject to applicable member contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. This Medical Policy has been developed through consideration of the medical necessity criteria under Hawaii s Patients Bill of Rights and Responsibilities Act (Hawaii Revised Statutes 432E-1.4), generally accepted standards of medical practice and review of medical literature and government approval status. HMSA has determined that services not covered under this Medical Policy will not be medically necessary under Hawaii law in most cases. If a treating physician disagrees with HMSA s determination as to medical necessity in a given case, the physician may request that CVS/caremark reconsider the application of the medical necessity criteria to the case at issue in light of any supporting documentation.

8 Keytruda 8 I. REFERENCES 1. Keytruda [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; May July National Cancer Comprehensive Network Drugs and Biologics Compendium. Available at Accessed November 22, 2016August 22 nd Document History 10/01/2015 Original effective date 02/2016 Added new indication, first-line melanoma 08/2016 Added new indication, head and neck cancer 11/2016 Added new indication, first-line NSCLC 12/2016 Annual update 05/01/2017 Revision effective date 06/2017 Added new/expanded indications: chl, NSCLC, urothelial carcinoma, MSI- H/dMMR solid tumors 07/24/2017 Revision effective date 08/2017 Annual Review 03/01/2018TBD Revision effective date

Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage

Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: TBD003/01/201703/01/2018 POLICY A. INDICATIONS The indications

More information

Cyramza (ramucirumab)

Cyramza (ramucirumab) Cyramza (ramucirumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 03/01/2017TBD03/01/2018 POLICY A. INDICATIONS The indications

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Pembrolizumab (Keytruda) Reference Number: CP.PHAR.322 Effective Date: 07.01.18 Last Review Date: 11.17 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda

More information

Policy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)

Policy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous) Nivolumab (Intravenous) NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3734-XX Opdivo 240

More information

Policy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab

Policy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB

More information

Opdivo. Opdivo (nivolumab) Description

Opdivo. Opdivo (nivolumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:

More information

Torisel (temsirolimus)

Torisel (temsirolimus) Torisel (temsirolimus) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 11/1/2017 POLICY A. INDICATIONS The indications below

More information

Torisel (temsirolimus)

Torisel (temsirolimus) Torisel (temsirolimus) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 11/01/2017TBD03/01/2017 POLICY A. INDICATIONS The indications

More information

Opdivo. Opdivo (nivolumab) Description

Opdivo. Opdivo (nivolumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:

Clinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date: Clinical Policy: (Opdivo) Reference Number: ERX.SPA.302 Effective Date: 03.01.19 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 6 Last Review Date: September 15, 2017 Keytruda Description Keytruda

More information

Perjeta (pertuzumab)

Perjeta (pertuzumab) Perjeta (pertuzumab) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201809/16/2018 POLICY A. INDICATIONS The indications

More information

Gazyva (obinutuzumab)

Gazyva (obinutuzumab) Gazyva (obinutuzumab) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201807/01/2018 POLICY A. INDICATIONS The indications

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Somatuline Depot (lanreotide)

Somatuline Depot (lanreotide) Somatuline Depot (lanreotide) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 12/01/2017TBD POLICY A. INDICATIONS The indications

More information

Clinical Policy: Pembrolizumab (Keytruda) Reference Number: CP.PHAR.322

Clinical Policy: Pembrolizumab (Keytruda) Reference Number: CP.PHAR.322 Clinical Policy: (Keytruda) Reference Number: CP.PHAR.322 Effective Date: 03/17 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

MEDICAL PRIOR AUTHORIZATION

MEDICAL PRIOR AUTHORIZATION MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Keytruda) Reference Number: CP.PHAR.322 Effective Date: 03.01.17 Last Review Date: 11.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder

More information

Velcade (bortezomib)

Velcade (bortezomib) Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 03/09/2004 Current Effective Date: 05/01/2017 POLICY A. INDICATIONS The indications below

More information

Velcade (bortezomib)

Velcade (bortezomib) Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 03/09/2004 Current Effective Date: 03/01/2018 POLICY A. INDICATIONS The indications below

More information

Erbitux. Erbitux (cetuximab) Description

Erbitux. Erbitux (cetuximab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.84 Subject: Erbitux Page: 1 of 6 Last Review Date: December 2, 2016 Erbitux Description Erbitux (cetuximab)

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC Clinical Policy: (Opdivo) Reference Number: CP.HNMC.27 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for

More information

CENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 April May

CENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 April May BRAND NAME Keytruda GENERIC NAME Pembrolizumab MANUFACTURER Merck & Co., Inc. DATE OF APPROVAL Non-small cell lung cancer (NSCLC) indication: May 10, 2017 Urothelial carcinoma indication: May 18, 2017

More information

Clinical Policy: Cetuximab (Erbitux) Reference Number: ERX.SPA.261 Effective Date:

Clinical Policy: Cetuximab (Erbitux) Reference Number: ERX.SPA.261 Effective Date: Clinical Policy: (Erbitux) Reference Number: ERX.SPA.261 Effective Date: 12.01.18 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Keytruda (pembrolizumab) (Intravenous)

Keytruda (pembrolizumab) (Intravenous) Keytruda (pembrolizumab) (Intravenous) Last Review Date: 02/06/2018 Date of Origin: 09/30/2014 Document Number: IC-0209 Dates Reviewed: 9/2014, 3/2015, 5/2015, 8/2015, 10/2015, 11/2015, 2/2016, 5/2016,

More information

Alimta (pemetrexed) Document Number: IC 0007

Alimta (pemetrexed) Document Number: IC 0007 Alimta (pemetrexed) Document Number: IC 0007 Last Review Date: 05/01/2018 Date of Origin: 07/20/2010 Dates Reviewed: 09/2010, 12/2010, 03/2011, 06/2011,0 9/2011, 12/2011, 03/2012, 06/2012, 09/2012, 12/2012,

More information

BLA /S-048, S-049, S-050, S-051, S-052, S-061, S-062, S-064, S-065, and S-066 SUPPLEMENT APPROVAL

BLA /S-048, S-049, S-050, S-051, S-052, S-061, S-062, S-064, S-065, and S-066 SUPPLEMENT APPROVAL DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 BLA 125554/S-048, S-049, S-050, S-051, S-052, S-061, S-062, S-064, S-065, and S-066 SUPPLEMENT APPROVAL Bristol-Myers

More information

May 31, NCCN Guidelines: T-Cell Lymphomas

May 31, NCCN Guidelines: T-Cell Lymphomas May 31, 2017 Maria Rivas, MD Senior Vice-President Global Medical Affairs Merck & Co. Kenilworth - Galloping Hill, +1 908 740 6533 K6-1624G maria.rivas1@merck.com NCCN Guidelines: T-Cell Lymphomas On behalf

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Erbitux) Reference Number: CP.PHAR.317 Effective Date: 02.01.17 Last Review Date: 11.18 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 5 Last Review Date: June 24, 2016 Keytruda Description Keytruda (pembrolizumab)

More information

Bevacizumab (Avastin)

Bevacizumab (Avastin) Bevacizumab (Avastin) Policy Number: Original Effective Date: MM.04.001 09/14/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2014 Section: Prescription Drugs Place(s) of Service:

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Ipilimumab (Yervoy) Reference Number: CP.PHAR.319 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important

More information

Yervoy. Yervoy (ipilimumab) Description

Yervoy. Yervoy (ipilimumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.13 Subject: Yervoy Page: 1 of 5 Last Review Date: September 15, 2017 Yervoy Description Yervoy (ipilimumab)

More information

Clinical Policy: Atezolizumab (Tecentriq) Reference Number: CP.PHAR.235 Effective Date: 06/16 Last Review Date: 05/17

Clinical Policy: Atezolizumab (Tecentriq) Reference Number: CP.PHAR.235 Effective Date: 06/16 Last Review Date: 05/17 Clinical Policy: (Tecentriq) Reference Number: CP.PHAR.235 Effective Date: 06/16 Last Review Date: 05/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important

More information

Drug Prior Authorization Form Opdivo (nivolumab)

Drug Prior Authorization Form Opdivo (nivolumab) This document contains both information and form fields. To read information, use the Down Arrow from a form field. Drug Prior Authorization Form The purpose of this form is to obtain information required

More information

CLINICAL MEDICATION POLICY

CLINICAL MEDICATION POLICY CLINICAL MEDICATION POLICY Policy Name: Opdivo (nivolumab) injection Policy Number: Approved By: Medical Management, Clinical Pharmacy Products: Highmark Health Options Application: All participating hospitals

More information

GROWTH HORMONE THERAPY

GROWTH HORMONE THERAPY GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 12/30/201601/01/2018TBD03/01/2018 POLICY A. INDICATIONS The indications

More information

Clinical Policy: Cetuximab (Erbitux) Reference Number: PA.CP.PHAR.317

Clinical Policy: Cetuximab (Erbitux) Reference Number: PA.CP.PHAR.317 Clinical Policy: (Erbitux) Reference Number: PA.CP.PHAR.317 Effective Date: 01/18 Last Review Date: 11/17 Coding Implications Revision Log Description The intent of the criteria is to ensure that patients

More information

Clinical Policy: Ramucirumab (Cyramza) Reference Number: CP.PHAR.119

Clinical Policy: Ramucirumab (Cyramza) Reference Number: CP.PHAR.119 Clinical Policy: (Cyramza) Reference Number: CP.PHAR.119 Effective Date: 05/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Tafinlar) Reference Number: CP.PHAR.239 Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Mekinist) Reference Number: CP.PHAR.240 Effective Date: 07.01.16 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of

More information

NCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018

NCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018 Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as

More information

Vectibix. Vectibix (panitumumab) Description

Vectibix. Vectibix (panitumumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.85 Subject: Vectibix Page: 1 of 5 Last Review Date: December 2, 2016 Vectibix Description Vectibix

More information

GROWTH HORMONE THERAPY

GROWTH HORMONE THERAPY GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 03/01/201804/01/2019 POLICY A. INDICATIONS The indications below including

More information

NCCN Non Small Cell Lung Cancer V Meeting July 8, 2016

NCCN Non Small Cell Lung Cancer V Meeting July 8, 2016 NSCL 3 Submission from Myriad requesting the following statement to be listed as an additional high risk factor in footnote p : For lung ADC, a highrisk 46 gene molecular prognostic score determined by

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Proteomic Testing for Targeted Therapy in Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomic_testing_for_targeted_therapy_in_non_small_cell_lung_cancer

More information

Clinical Policy: Erlotinib (Tarceva) Reference Number: CP.PHAR74 Effective Date: Last Review Date: Line of Business: Oregon Health Plan

Clinical Policy: Erlotinib (Tarceva) Reference Number: CP.PHAR74 Effective Date: Last Review Date: Line of Business: Oregon Health Plan Clinical Policy: (Tarceva) Reference Number: CP.PHAR74 Effective Date: 07.01.18 Last Review Date: 02.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy

More information

Bortezomib (Velcade)

Bortezomib (Velcade) Bortezomib (Velcade) Policy Number: Original Effective Date: MM.04.003 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription Drugs Place(s)

More information

Vectibix (panitumumab) will be considered medically necessary when all of the following criteria are met:

Vectibix (panitumumab) will be considered medically necessary when all of the following criteria are met: What s New Medical Pharmaceutical Policy November 2017 Updates MBP 40.0 Orencia IV (abatacept)- New Indication Orencia IV (abatacept) will be considered medically necessary when all of the following criteria

More information

Management of advanced non small cell lung cancer

Management of advanced non small cell lung cancer Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict

More information

NCCN Guidelines for Hepatobiliary Cancers V Web teleconference on 10/24/17

NCCN Guidelines for Hepatobiliary Cancers V Web teleconference on 10/24/17 Guideline Page and Request HCC-4 the American Society of Radiation Oncology (ASTRO): We recommend further clarification of the eligibility criteria for surgical resection and liver transplantation, respectively.

More information

General Information, efficacy and safety data

General Information, efficacy and safety data Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie

More information

KEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.

KEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for

More information

Dupixent (dupilumab)

Dupixent (dupilumab) Dupixent (dupilumab) Line(s) of Business: HMO; PPO; QUEST Integration Effective Date: TBD POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered

More information

Histology independent indications in Oncology

Histology independent indications in Oncology CHMP Oncology Working Party Workshop Histology independent indications in Oncology What have we learnt from the anti PD1- PDL1 story? J Camarero (CHMP alternate ES, OncWP) Disclaimers the views presented

More information

Non-Small Cell Lung Cancer:

Non-Small Cell Lung Cancer: Non-Small Cell Lung Cancer: Where We Are Today Sila Shalhoub, PharmD PGY2 Oncology Pharmacy Resident Shalhoub.Sila@mayo.edu Pharmacy Grand Rounds September 26, 2017 2017 MFMER slide-1 Objectives Identify

More information

CLINICAL MEDICATION POLICY

CLINICAL MEDICATION POLICY Policy Name: Policy Number: Approved By: CLINICAL MEDICATION POLICY Keytruda (pembrolizumab) MP-014-MD-DE Medical Management; Clinical Pharmacy Provider Notice Date: 01/15/2018; 08/01/2017; 06/01/2016

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy 11/13, 10/12, 11/11, 1, 6/10, Page 1 of 5 DESCRIPTION: Cetuximab is a recombinant humanized monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor

More information

General Information, efficacy and safety data

General Information, efficacy and safety data Horizon Scanning in Oncology Horizon Scanning in Oncology 33 r d Prioritization 4 t h quarter 2017 General Information, efficacy and safety data Nicole Grössmann Sarah Wolf Please note: Within this document

More information

Immunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care

Immunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications

More information

Incorporating Immunotherapy into the treatment of NSCLC

Incorporating Immunotherapy into the treatment of NSCLC Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Imfinzi) Reference Number: CP.PHAR.339 Effective Date: 07.01.17 Last Review Date: 05.18 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important

More information

Immunotherapy in head and neck cancer and MSI in solid tumors

Immunotherapy in head and neck cancer and MSI in solid tumors Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology

More information

Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment

Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Emily Borders, Pharm.D., M.S., BCOP Oncology Clinical Pharmacist Stephenson Cancer Center Faculty Disclosure Learning Objectives

More information

Tecentriq. Tecentriq (atezolizumab) Description

Tecentriq. Tecentriq (atezolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.80 Subject: Tecentriq Page: 1 of 5 Last Review Date: September 15, 2017 Tecentriq Description Tecentriq

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Stivarga) Reference Number: CP.PHAR.107 Effective Date: 12.01.12 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of

More information

Review of NEO Testing Platforms. Lawrence M. Weiss, MD Medical Director, Aliso Viejo

Review of NEO Testing Platforms. Lawrence M. Weiss, MD Medical Director, Aliso Viejo Review of NEO Testing Platforms Lawrence M. Weiss, MD Medical Director, Aliso Viejo Lawrence Weiss, M.D. Medical Director, Aliso Viejo Dr. Weiss currently serves as NeoGenomics Medical Director, Aliso

More information

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations Gong et al. Journal for ImmunoTherapy of Cancer (2018) 6:8 DOI 10.1186/s40425-018-0316-z REVIEW Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration

More information

Clinical Policy: Temozolomide (Temodar) Reference Number: ERX.SPA.138 Effective Date:

Clinical Policy: Temozolomide (Temodar) Reference Number: ERX.SPA.138 Effective Date: Clinical Policy: (Temodar) Reference Number: ERX.SPA.138 Effective Date: 03.01.14 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Understanding your treatment and the side effects you may experience

Understanding your treatment and the side effects you may experience Understanding your treatment and the side effects you may experience What does treat? is a prescription medicine used in combination with YERVOY to treat a type of skin cancer called melanoma that has

More information

StrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient

StrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient StrandAdvantage Tissue-Specific Cancer Genomic Tests Empowering Crucial First-Line Therapy Decisions for Your Patient Harness the power of precision medicine with StrandAdvantage Precision medicine in

More information

ICLIO National Conference

ICLIO National Conference ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency

More information

Clinical Policy: Ramucirumab (Cyramza) Reference Number: CP.HNMC.09 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC

Clinical Policy: Ramucirumab (Cyramza) Reference Number: CP.HNMC.09 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC Clinical Policy: (Cyramza) Reference Number: CP.HNMC.09 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Stivarga) Reference Number: CP.CPA.157 Effective Date: 11.16.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy

More information

Clinical Policy: Pemetrexed (Alimta) Reference Number: CP.PHAR.368 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Pemetrexed (Alimta) Reference Number: CP.PHAR.368 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Alimta) Reference Number: CP.PHAR.368 Effective Date: 10.31.17 Last Review Date: 02.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of

More information

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/

More information

GROWTH HORMONE THERAPY

GROWTH HORMONE THERAPY GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below including FDA-approved

More information

KEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.

KEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for

More information

GENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)

GENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC) CANCER (NSCLC) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are

More information

Dr. Andres Wiernik. Lung Cancer

Dr. Andres Wiernik. Lung Cancer Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional

More information

KEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S.

KEYTRUDA (pembrolizumab) for injection, for intravenous use KEYTRUDA (pembrolizumab) injection, for intravenous use Initial U.S. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (pembrolizumab) for injection, for

More information

Clinical Policy: Topotecan (Hycamtin) Reference Number: CP.PHAR.64 Effective Date: Last Review Date: Line of Business: Medicaid, HIM

Clinical Policy: Topotecan (Hycamtin) Reference Number: CP.PHAR.64 Effective Date: Last Review Date: Line of Business: Medicaid, HIM Clinical Policy: (Hycamtin) Reference Number: CP.PHAR.64 Effective Date: 06.01.11 Last Review Date: 05.18 Line of Business: Medicaid, HIM Coding Implications Revision Log See Important Reminder at the

More information

Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories

Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion

More information

HIGHLIGHTS OF PRESCRIBING INFORMATION

HIGHLIGHTS OF PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OPDIVO safely and effectively. See full prescribing information for OPDIVO. OPDIVO (nivolumab) injection,

More information

Xolair (omalizumab) Limitation of Use: Xolair is not indicated for treatment of other forms of urticaria.

Xolair (omalizumab) Limitation of Use: Xolair is not indicated for treatment of other forms of urticaria. Xolair (omalizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 11/18/2003 Current Effective Date: 12/01/2017TBD POLICY A. INDICATIONS The indications below

More information

Approval of pembrolizumab (MSI- H/dMMR) and considerations for site-agnostic development of drugs in oncology

Approval of pembrolizumab (MSI- H/dMMR) and considerations for site-agnostic development of drugs in oncology Approval of pembrolizumab (MSI- H/dMMR) and considerations for site-agnostic development of drugs in oncology Steven Lemery, MD, MHS Associate Director, DOP2 Traditional development paradigm Based on tumor

More information

Subject: Ipilimumab (Yervoy ) Injection

Subject: Ipilimumab (Yervoy ) Injection 09-J1000-34 Original Effective Date: 08/15/11 Reviewed: 03/14/18 Revised: 12/15/18 Subject: Ipilimumab (Yervoy ) Injection THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION

More information

(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018

(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018 August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of

More information

Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17

Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17 Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic

More information